STOCK TITAN

Emergent BioSolutions (EBS) SVP reports 1,741-share tax withholding on RSU vesting

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Emergent BioSolutions Inc. Senior Vice President of Bioservices William Hartzel reported a routine tax-related share disposition. On June 8, 2026, 1,741 shares of common stock were withheld at $8.00 per share to cover taxes from the vesting and settlement of restricted stock units. After this withholding, Hartzel directly held 185,558 shares of Emergent BioSolutions common stock. This was not an open-market sale but an automatic tax-withholding mechanism tied to equity compensation.

Positive

  • None.

Negative

  • None.
Insider Hartzel William
Role SVP, Bioservices
Type Security Shares Price Value
Exercise Price or Tax Liability Common Stock 1,741 $8.00 $14K
Holdings After Transaction: Common Stock — 185,558 shares (Direct)
Footnotes (1)
  1. F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Shares withheld for taxes 1,741 shares Tax-withholding disposition on June 8, 2026
Withholding price per share $8.00 per share Value used for tax-withholding shares
Shares held after transaction 185,558 shares Direct ownership after June 8, 2026 Form 4
tax-withholding disposition financial
"A total of 1,741 Emergent BioSolutions common shares were withheld for William Hartzel’s tax obligations."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
restricted stock units financial
"shares were connected to the vesting and settlement of restricted stock units granted as part of his compensation package."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 4 regulatory
"This post-transaction balance shown in the Form 4 indicates that the withholding affected only a small portion of his overall share position."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Emergent BioSolutions (EBS) report for William Hartzel?

Emergent BioSolutions reported a tax-related share disposition by SVP, Bioservices, William Hartzel. On June 8, 2026, 1,741 common shares were withheld to cover taxes from vesting restricted stock units, a standard equity compensation mechanism rather than an open-market stock sale.

How many Emergent BioSolutions (EBS) shares were withheld for William Hartzel’s taxes?

A total of 1,741 Emergent BioSolutions common shares were withheld for William Hartzel’s tax obligations. The shares were valued at $8.00 per share and were connected to the vesting and settlement of restricted stock units granted as part of his compensation package.

Was William Hartzel’s Emergent BioSolutions (EBS) Form 4 a stock sale on the market?

The Form 4 does not show an open-market sale by William Hartzel. Instead, 1,741 shares were withheld by the company to pay taxes on vested restricted stock units, which is a routine administrative transaction associated with equity compensation programs.

How many Emergent BioSolutions (EBS) shares does William Hartzel hold after this transaction?

Following the tax-withholding transaction, William Hartzel directly held 185,558 shares of Emergent BioSolutions common stock. This post-transaction balance shown in the Form 4 indicates that the withholding affected only a small portion of his overall share position.

What does transaction code F mean in the Emergent BioSolutions (EBS) Form 4?

Transaction code F indicates shares were used to pay exercise price or tax liability. In this case, 1,741 Emergent BioSolutions shares were withheld to satisfy taxes from the vesting and settlement of restricted stock units, rather than being sold in the open market.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hartzel William

(Last)(First)(Middle)
300 PROFESSIONAL DRIVE

(Street)
GAITHERSBURG MARYLAND 20879

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, Bioservices
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/08/2026F1,741(1)D$8185,558D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Remarks:
/s/ Richard S. Lindahl, Attorney-in-fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)